The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.
  • The agreement for the distribution of Sentia runs for three years and can be renewed and terminated by either company
  • Sentia analyses sulphur dioxide in post-fermentation white and red wine in a quick and accurate manner
  • Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage
  • UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents

Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.

The distribution period for the Sentia device runs for three years and can be renewed and terminated by either company.

“We are delighted to partner with Sentia in the United States. We have received positive feedback from our customers and believe Sentia will make a significant impact in the wine testing market in the USA,” Wine & Beer Supply CEO Dave Robertson said.

It’s been a busy couple of days for UBI, entering an agreement with Singularity SpA for the distribution of Sentia in Chile just yesterday.

Sentia analyses sulphur dioxide in post-fermentation white and red wine. Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage.

Results are then received in under a minute instead of the several days it takes a lab.

“Securing another distributor in the U.S. is a positive step in the commercialisation of Sentia globally,” UBI CEO John Sharman commented.

“Wine & Beer Supply has a strong presence in the U.S., particularly in the eastern half of the U.S. and will give Sentia greater access to the 11,500 wineries across the country,” he added.

UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents in a $129.6 million market cap.

UBI by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…